Samsara BioCapital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-700,421
| Closed | -$925K | – | 62 |
|
|
2022
Q1 | $925K | Hold |
700,421
| – | – | 0.23% | 46 |
|
|
2021
Q4 | $946K | Hold |
700,421
| – | – | 0.18% | 46 |
|
|
2021
Q3 | $2.04M | Hold |
700,421
| – | – | 0.32% | 40 |
|
|
2021
Q2 | $2.44M | Hold |
700,421
| – | – | 0.3% | 41 |
|
|
2021
Q1 | $2.4M | Sell |
700,421
-115,000
| -14% | -$2.17M | 0.44% | 38 |
|
|
2020
Q4 | $15.7K | Hold |
815,421
| – | – | 1.57% | 10 |
|
|
2020
Q3 | $11M | Buy |
815,421
+318,916
| +64% | +$9.03M | 3.05% | 11 |
|
|
2020
Q2 | $21M | Sell |
496,505
-26,132
| -5% | -$846K | 6.76% | 3 |
|
|
2020
Q1 | $14.4M | Hold |
522,637
| – | – | 8.3% | 4 |
|
|
2019
Q4 | $17M | Hold |
522,637
| – | – | 8.13% | 4 |
|
|
2019
Q3 | $13.6M | Sell |
522,637
-93,213
| -15% | -$3.12M | 9.26% | 5 |
|
|
2019
Q2 | $22.6M | Buy |
615,850
+20,000
| +3% | +$479K | 14.93% | 2 |
|
|
2019
Q1 | $13.2M | Hold |
595,850
| – | – | 10.35% | 3 |
|
|
2018
Q4 | $8.39M | Buy |
+595,850
| New | +$9.28M | 8.05% | 5 |
|
Samsara BioCapital's ODT Position: Q2 2022 in Review
Samsara BioCapital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2022, closing a stake of 700,421 shares — an estimated $925K sold.
Samsara BioCapital first reported a position in ODT in Q4 2018 and held it in 14 quarters. The position peaked at $22.6M in Q2 2019. 0 funds tracked by Wall St. Rank hold ODT as of Q2 2022.
- Samsara BioCapital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
- Samsara BioCapital sold 700,421 Odonate Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $925K.
- Samsara BioCapital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2018 and held it in 14 quarters.
- Samsara BioCapital's Odonate Therapeutics, Inc. Common Stock position peaked at $22.6M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2022.
Based on Samsara BioCapital's 13F filing for Q2 2022, filed 15 Aug 2022.